Evrópusambandið - maltneska - EMA (European Medicines Agency)

celgene europe bv - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - aġenti antineoplastiċi - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Evrópusambandið - maltneska - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - aġenti antineoplastiċi - azacitidine betapharm huwa indikat għall-kura ta 'pazjenti adulti li mhumiex eliġibbli għat-trapjanti ta'ċelloli staminali ematopojetiċi (hsct) bil -: intermedji-2 u ta' riskju sindromi majelodisplastiċi (mds) skond l-international pronostiċi scoring system (ipss),lewkimja majelomonoċitika kronika (cmml) b'10 % sa 29 % tal-mudullun tal-blasts mingħajr disturbi majeloproliferattivi,lewkimja majelojde akuta (aml) b'20 % sa 30 % blasts u multi-lineage-displażija, skond l-organizzazzjoni dinjija tas-saħħa (who) il-klassifikazzjoni,l-aml b ' > 30 % tal-mudullun tal-blasts skond il-klassifikazzjoni tal-who.

Evrópusambandið - maltneska - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - aġenti antineoplastiċi - azacitidine qbil huwa indikat għall-kura ta 'pazjenti adulti li mhumiex eliġibbli għat-trapjanti ta'ċelloli staminali ematopojetiċi (hsct) bil -: - intermedja-2 u ta' riskju sindromi majelodisplastiċi (mds) skond l-international pronostiċi scoring system (ipss),- lewkimja majelomonoċitika kronika (cmml) b'10-29 % tal-mudullun tal-blasts mingħajr majeloproliferattivi-disturb, il - lewċemija mjelojde akuta (aml) b'20-30 % blasts u multi-lineage-displażija, skond l-organizzazzjoni dinjija tas-saħħa (who) il-klassifikazzjoni, l - aml b ' >30% tal-mudullun tal-blasts skond il-klassifikazzjoni tal-who.

Evrópusambandið - maltneska - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - aġenti antineoplastiċi - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Evrópusambandið - maltneska - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - aġenti antineoplastiċi - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. għal aktar informazzjoni dwar l-istatus tal-fattur tat-tkabbir tal-epidermide tal-bniedem 2 (her2), jekk jogħġbok irreferi għat-taqsima 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. għal aktar informazzjoni dwar l-istatus ta 'her2, jekk jogħġbok irreferi għat-taqsima 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Evrópusambandið - maltneska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - aġenti antineoplastiċi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Evrópusambandið - maltneska - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicin hydrochloride - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - aġenti antineoplastiċi - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Evrópusambandið - maltneska - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - leukimija limfoblastika taċ-Ċelluli prekursuri-linfoma - aġenti antineoplastiċi - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Evrópusambandið - maltneska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - docetaxel - stomach neoplasms; adenoma; breast neoplasms; carcinoma, non-small-cell lung; prostatic neoplasms - aġenti antineoplastiċi - tas-sider cancerdocetaxel flimkien ma 'doxorubicin u cyclophosphamide huwa indikat għall-kura awżiljarja ta' pazjenti b'operabbli node-kanċer tas-sider posittiv. docetaxel flimkien ma 'doxorubicin huwa indikat għat-trattament ta' pazjenti b'avvanzat lokalment jew metastatiku tas-sider tal-kanċer li ma kinux ħadu qabel terapija ċitotossika għal din il-kundizzjoni. b'docetaxel bħala monoterapija hija indikata għat-trattament ta 'pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment ta' terapija ċitotossika. kemjoterapija preċedenti kellha tinkludi anthracycline jew aġent alkilanti. docetaxel flimkien ma 'trastuzumab huwa indikat għat-trattament ta' pazjenti b'kanċer tas-sider metastatiku li t-tumuri tagħhom fuq jesprimu her2, u li preċedentement ma kienux ħadu kimoterapija għall-mard metastatiku. docetaxel flimkien ma 'capecitabine huwa indikat għat-trattament ta' pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment tal-kimoterapija ċitotossika. it-terapija ta 'qabel kellha tinkludi anthracycline. taċ-ċelluli mhux żgħar tal-pulmun cancerdocetaxel huwa indikat għall-kura ta ' pazjenti b'lokalment avvanzat jew metastatiku taċ-ċelluli mhux żgħar tal-pulmun il-kanċer wara l-falliment tal-kimoterapija qabel. docetaxel flimkien ma 'cisplatin huwa indikat għat-trattament ta' pazjenti li ma jistax jitneħħa, avvanzat lokalment jew metastatiku taċ-ċelluli mhux żgħar tal-pulmun il-kanċer, f'pazjenti li ma kinux ħadu qabel terapija ċitotossika għal din il-kundizzjoni. - prostata cancerdocetaxel flimkien ma 'prednisone jew prednisolone huwa indikat għat-trattament ta' pazjenti bl-ormon tat-refrattarji kanċer metastatiku tal-prostata. - istonku adenocarcinomadocetaxel flimkien ma 'cisplatin u 5-fluorouracil huwa indikat għat-trattament ta' pazjenti b'adenokarċinoma gastrika metastatika, inkluż l-adenokarċinoma ta ' l-istonku junction, li ma ħadu l-kimoterapija qabel, għal mard metastatiku. - ras u l-għonq cancerdocetaxel flimkien ma 'cisplatin u 5-fluorouracil huwa indikat għat-trattament induttiv ta' pazjenti b'lokalment avvanzat tal-karċinoma b'ċelloli squamous tar-ras u l-għonq.

Evrópusambandið - maltneska - EMA (European Medicines Agency)

teva pharma b.v. - docetaxel - carcinoma, non-small-cell lung; breast neoplasms; prostatic neoplasms - aġenti antineoplastiċi - tas-sider cancerdocetaxel teva pharma monoterapija hija indikata għat-trattament ta 'pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment ta' terapija ċitotossika. kemjoterapija preċedenti kellha tinkludi anthracycline jew aġent alkilanti. mhux żgħar tal-pulmun taċ-ċelluli cancerdocetaxel teva pharma huwa indikat għall-kura ta ' pazjenti b'lokalment avvanzat jew dak metastatiku li mhux żgħar tal-pulmun taċ-ċelloli tal-kanċer wara l-falliment tal-kimoterapija qabel. docetaxel teva pharma flimkien ma 'cisplatin huwa indikat għat-trattament ta' pazjenti li ma jistax jitneħħa, avvanzat lokalment jew dak metastatiku li mhux żgħar tal-pulmun taċ-ċelluli tal-kanċer, f'pazjenti li ma kinux ħadu qabel terapija ċitotossika għal din il-kundizzjoni. - prostata cancerdocetaxel teva pharma flimkien ma 'prednisone jew prednisolone huwa indikat għat-trattament ta' pazjenti bl-ormon tat-refrattarji kanċer metastatiku tal-prostata.